CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 84 filers reported holding CTI BIOPHARMA CORP in Q2 2018. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $534,920 | -47.2% | 127,362 | -24.4% | 0.00% | – |
| Q4 2022 | $1,012,752 | -69.7% | 168,511 | -70.6% | 0.00% | -100.0% |
| Q3 2022 | $3,337,000 | -38.7% | 573,497 | -37.1% | 0.00% | 0.0% |
| Q2 2022 | $5,448,000 | +595.8% | 912,474 | +444.7% | 0.00% | – |
| Q1 2022 | $783,000 | +207.1% | 167,506 | +62.9% | 0.00% | – |
| Q4 2021 | $255,000 | -3.8% | 102,816 | +14.4% | 0.00% | – |
| Q3 2021 | $265,000 | +84.0% | 89,873 | +56.0% | 0.00% | – |
| Q2 2021 | $144,000 | -79.5% | 57,600 | -76.1% | 0.00% | – |
| Q1 2021 | $702,000 | +120.8% | 241,206 | +144.3% | 0.00% | – |
| Q4 2020 | $318,000 | +249.5% | 98,741 | +132.3% | 0.00% | – |
| Q3 2020 | $91,000 | +237.0% | 42,500 | +45.1% | 0.00% | – |
| Q1 2020 | $27,000 | -34.1% | 29,289 | -30.3% | 0.00% | – |
| Q1 2019 | $41,000 | -37.9% | 42,000 | -53.1% | 0.00% | – |
| Q4 2018 | $66,000 | -56.0% | 89,495 | +29.4% | 0.00% | – |
| Q3 2018 | $150,000 | -22.7% | 69,169 | +78.4% | 0.00% | – |
| Q2 2018 | $194,000 | +212.9% | 38,780 | +68.5% | 0.00% | – |
| Q4 2017 | $62,000 | – | 23,018 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 3,904,400 | $3,355,000 | 2.31% |
| BVF INC/IL | 6,929,690 | $5,955,000 | 0.65% |
| CAXTON CORP | 324,452 | $279,000 | 0.32% |
| NEA Management Company, LLC | 3,750,000 | $3,222,000 | 0.23% |
| Orbimed Advisors | 5,000,000 | $4,297,000 | 0.07% |
| Fosun International Ltd | 459,274 | $390,000 | 0.03% |
| Paloma Partners Management Co | 229,800 | $197,000 | 0.00% |
| OXFORD ASSET MANAGEMENT LLP | 127,602 | $110,000 | 0.00% |
| LMR Partners LLP | 54,931 | $47,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 17,495 | $15,000 | 0.00% |